Indoco Remedies Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: INDOCO BSE: 532612

₹261.67

Sept. 30, 2026 · NSE · nse_bhavcopy

Peers in Pharmaceuticals & Biotechnology

The largest companies in the same industry by market cap. This company ranks #74 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.

Company	Market cap (₹ Cr)	PE (TTM)	ROE	1Y return	Div. yield	Quality	Valuation	Momentum
Sun Pharmaceutical Industries Limited	435,863	146.5	13.7%	11.0%	—	72	8	30
Divi's Laboratories Limited	246,660	83.9	15.3%	62.7%	0.32%	70	4	51
Torrent Pharmaceuticals Limited	162,454	78.2	12.2%	34.6%	0.79%	56	0	31
Zydus Lifesciences Limited	115,910	33.3	17.3%	17.2%	0.09%	74	24	84
Cipla Limited	108,736	35.4	11.2%	-11.0%	0.97%	73	29	62
Laurus Labs Limited	106,969	122.5	17.1%	127.1%	—	78	24	53
Mankind Pharma Limited	103,406	47.4	11.7%	2.6%	—	68	12	86
Dr. Reddy's Laboratories Limited	102,916	154.7	10.9%	-0.9%	—	62	33	71
Indoco Remedies Limited (this stock)	2,415	23.1	-10.6%	-9.8%	—	46	72	85

Valuation multiples

Current only. Market cap is the whole company's; sales/EBITDA are trailing-twelve-month standalone; debt and cash come from the latest filed standalone balance sheet (March 31, 2026). EBITDA = PBT + interest + depreciation.

Enterprise value

₹3,108 Cr

EV / EBITDA

10.1x

EV / Sales

1.83x

Market cap / Sales

1.42x

Earnings yield

4.33%

Quarterly Financials

Download CSV

Standalone Consolidated

↑ Positive

Quarterly Revenue

Jun 2026 quarterly revenue is Rs 413 Cr, up 3.9% YoY.

Period end	Revenue (₹ Cr)	PBT (₹ Cr)	Net profit (₹ Cr)	Basic EPS
June 30, 2026	409	93	82	₹8.9200
March 31, 2026	449	28	27	₹2.9600
Dec. 31, 2025	401	-20	-20	₹-2.1700
Sept. 30, 2025	442	10	15	₹1.6300
June 30, 2025	393	-28	-28	₹-3.0400
March 31, 2025	347	-31	-26	₹-2.8500
Dec. 31, 2024	373	-13	-10	₹-1.1100
Sept. 30, 2024	397	17	13	₹1.3900
June 30, 2024	401	20	15	₹1.6200
March 31, 2024	445	46	38	₹4.0800
Dec. 31, 2023	449	27	20	₹2.1700
Sept. 30, 2023	473	44	33	₹3.6000
June 30, 2023	423	36	26	₹2.8100

Quarterly income statement (standalone, ₹ Cr)

Indicator	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23
Total income (before exceptional items)	413	459	408	449	398	354	377	401	405	450	452	475	423
Operating revenue	409	449	401	442	393	347	373	397	401	445	449	473	423
Other income	4	10	7	7	6	6	4	4	4	4	3	1	0
Operating expenses	367	386	375	389	378	344	353	344	350	388	384	401	360
Operating profit	42	63	26	53	15	3	20	53	52	57	65	72	63
Operating profit margin	10.3%	14.0%	6.5%	12.1%	3.8%	1.0%	5.4%	13.3%	12.8%	12.9%	14.5%	15.3%	14.9%
Depreciation	28	27	27	28	25	25	25	25	24	24	23	21	20
Interest	23	23	20	22	24	16	14	15	12	11	10	8	8
Exceptional items, gain / (loss)	97	4	-6	-1	—	—	1	—	—	20	-8	—	—
Profit before tax	93	28	-20	10	-28	-31	-13	17	20	46	27	44	36
Tax	11	0	-0	-5	-0	-5	-3	5	5	9	7	11	10
Net profit	82	27	—	—	—	—	-10	13	15	38	20	33	26
EPS	8.92	2.96	-2.17	1.63	-3.04	-2.85	-1.11	1.39	1.62	4.08	2.17	3.60	2.81
Net profit (TTM)	—	—	—	—	—	—	55	85	106	117	104	112	129
EPS (TTM)	11.34	-0.62	-6.43	-5.37	-5.61	-0.95	5.98	9.26	11.47	12.66	11.33	12.18	13.97

Total income excludes exceptional items, which are shown on their own row. Trendlyne and Screener fold exceptional items into revenue or other income, so their totals differ from this table by exactly that row.

Annual Financials

Year ended	Revenue (₹ Cr)	PBT (₹ Cr)	Net profit (₹ Cr)
March 31, 2026	1,686	-11	-6
March 31, 2025	1,518	-7	-9
March 31, 2024	1,791	153	117
March 31, 2023	1,667	192	141

Annual income statement (standalone, ₹ Cr; CAGR to the latest year)

Indicator	CAGR 3Y	CAGR 5Y	Mar 26	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18	Mar 17
Total income (before exceptional items)	0.9%	6.7%	1,716^†	1,537^†	1,799^†	1,669^†	1,542^†	1,243^†	1,108^†	974^†	1,046^†	843^†
Operating revenue	0.4%	6.3%	1,686	1,518	1,791	1,667	1,540^†	1,240^†	1,106^†	968^†	1,042^†	839^†
Other income	—	—	30^†	18^†	9^†	2^†	2^†	3^†	2^†	6^†	5^†	4^†
Operating expenses	—	—	1,527^†	1,390^†	1,533^†	1,382^†	1,213^†	1,017^†	983^†	891^†	907^†	928^†
Operating profit	-17.7%	-6.6%	159^†	128^†	258^†	285^†	327^†	224^†	123^†	77^†	135^†	-88^†
Operating profit margin	—	—	9.4%^†	8.4%^†	14.4%^†	17.1%^†	21.2%^†	18.0%^†	11.2%^†	7.9%^†	12.9%^†	-10.5%^†
Depreciation	—	—	107^†	98^†	88^†	71^†	79^†	73^†	71^†	72^†	68^†	63^†
Interest	—	—	88^†	57^†	37^†	25^†	14^†	22^†	26^†	21^†	24^†	8^†
Exceptional items, gain / (loss)	—	—	-3^†	1^†	12^†	0^†	0^†	0^†	0^†	0^†	0^†	0^†
Profit before tax	—	—	-11	-7	153	192	236^†	131^†	29^†	-9^†	48^†	91^†
Tax	—	—	-6^†	1^†	37^†	50^†	82^†	39^†	4^†	—	7^†	14^†
Net profit	—	—	-6	-9	117	141	155^†	92^†	24^†	-3^†	—	77^†
EPS	—	—	-0.62^†	-0.95^†	12.66^†	15.33^†	16.77^†	10.02^†	2.64^†	—	—	—

^† Derived: the sum of that fiscal year's four quarterly filings (a real annual filing is used wherever one exists). Checked against filed annual figures, the sum lands within 0.5% for about 94% of company-years.

Annual ratios (standalone)

Ratio	Mar 26	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18	Mar 17
Operating margin	9.4%^†	8.4%^†	14.4%^†	17.1%^†	21.2%^†	18.0%^†	11.2%^†	7.9%^†	12.9%^†	-10.5%^†
EBIT margin	4.6%^†	3.2%^†	10.6%^†	13.0%^†	16.3%^†	12.4%^†	5.0%^†	1.2%^†	6.9%^†	11.9%^†
PBT margin	-0.7%	-0.5%	8.6%	11.5%	15.3%^†	10.6%^†	2.6%^†	-1.0%^†	4.6%^†	10.9%^†
Net margin	-0.3%	-0.6%	6.5%	8.5%	10.0%^†	7.4%^†	2.2%^†	-0.3%^†	—	9.2%^†
Interest coverage	0.87x^†	0.87x^†	5.16x^†	8.65x^†	17.71x^†	6.91x^†	2.09x^†	0.55x^†	3.06x^†	11.76x^†
Dividend payout	—	—	—	—	—	—	—	—	—	—
Earnings retention	—	—	—	—	—	—	—	—	—	—
Current ratio	1.27x	1.37x	—	—	—	—	—	—	—	—
Quick ratio	0.90x	0.85x	—	—	—	—	—	—	—	—
Debt to equity	0.64x	0.68x	—	—	—	—	—	—	—	—
Return on equity	-0.5%	-0.8%	—	—	—	—	—	—	—	—
Return on assets	-0.2%	-0.4%	—	—	—	—	—	—	—	—
Return on capital employed	5.2%^†	3.3%^†	—	—	—	—	—	—	—	—
Asset turnover	0.71x	0.69x	—	—	—	—	—	—	—	—

Margins and asset turnover use operating revenue (interest earned for banks, excluding other income), not total income. Liquidity, leverage and return ratios need a filed standalone balance sheet, which exists only for recent years; returns use year-end equity/assets. Dividend payout is shown only for companies with a dividend record. † = built from a summed fiscal year.

Revenue Mix

Data unavailable.

Cash Flow

Year ended	Operating (₹ Cr)	Investing (₹ Cr)	Financing (₹ Cr)	Capex (₹ Cr)	Free Cash Flow (₹ Cr)
March 31, 2026	226	-87	-133	125	101
March 31, 2025	91	-260	169	258	-168
March 31, 2024	177	-302	122	179	-2
March 31, 2023	176	-205	23	189	-14
March 31, 2022	174	-121	-44	125	48

Balance Sheet (standalone)

Year ended	Total Assets (₹ Cr)	Total Equity (₹ Cr)	Reserves (₹ Cr)	Borrowings, Current (₹ Cr)	Borrowings, Non-current (₹ Cr)	Current Assets (₹ Cr)	Current Liabilities (₹ Cr)	Cash & Equivalents (₹ Cr)	Net Block (₹ Cr)	Inventory (₹ Cr)
March 31, 2026	2,365	1,099	1,081	404	302	1,114	875	13	703	322
March 31, 2025	2,201	1,103	1,085	407	346	955	695	7	671	363
March 31, 2024	—	—	—	—	—	—	—	—	—	—
March 31, 2023	—	—	—	—	—	—	—	—	—	—
March 31, 2022	—	—	—	—	—	—	—	—	—	—

Financial charts

Trend charts drawn from the standalone income-statement and ratio tables above (oldest year on the left); a gap means that period has no figure. Annual years marked † in the tables are derived from four quarters.